SAM
ZNTL icon

Smartleaf Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Smartleaf Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-68
Closed -$198 – 3021
2024
Q4 		$198 Sell
68
-597
-90% -$1.96K ﹤0.01% 2868
2024
Q3 		$2.49K Buy
665
+177
+36% +$643 ﹤0.01% 2409
2024
Q2 		$2.05K Buy
+488
New +$5.45K ﹤0.01% 2216

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smartleaf Asset Management's ZNTL Position: Q1 2025 in Review

Smartleaf Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 68 shares — an estimated $198 sold.

Smartleaf Asset Management first reported a position in ZNTL in Q2 2024 and held it in 3 quarters. The position peaked at $2.49K in Q3 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Smartleaf Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 68 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $198.
  • Smartleaf Asset Management first reported a position in Zentalis Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Smartleaf Asset Management's Zentalis Pharmaceuticals position peaked at $2.49K in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Smartleaf Asset Management's 13F filing for Q1 2025, filed 14 May 2025.